Tesamorelin vs Ipamorelin: A Comparison

In this blog, we will compare Tesamorelin and Ipamorelin, two growth hormone-releasing peptides. We will delve into their mechanisms of action, potential effects, and side effects. The article also compares these two peptides, highlighting their differences and potential applications in the medical field.
Frederika Malichová

Frederika Malichová

Neuroscientist at the University Of Cambridge.

A blue image with text saying "Comparing Tesamorelin and Ipamorelin"

Comparing Tesamorelin and Ipamorelin

Tesamorelin and Ipamorelin are both growth hormone-releasing peptides, but they have different mechanisms of action. Tesamorelin specifically targets the release of growth hormone from the pituitary gland, while Ipamorelin stimulates the production of growth hormone throughout the body. These differences can influence their effects and potential side effects. There may not be sufficient evidence to answer exactly as the provided articles do not contain information about Tesamorelin. Please refer to reliable medical sources or consult a healthcare professional for accurate information about Tesamorelin.

What is Tesamorelin?

Tesamorelin is a synthetic molecule, which can be used as a substitute for human growth hormone releasing factor (GFR). GFR stimulates the synthesis and release of endogenous growth hormone.

Tesamorelin has been developed as a potential treatment for a variety of conditions related to the deficiency of growth hormone, including HIV-related lipodystrophy [1].

So far, tesamorelin is the only treatment which can reduce the excess abdominal fat in patients with HIV-associated lipodystrophy [2]. It also seems to significantly decrease waist circumference and visceral adipose tissue [3]

In addition to these, tesamorelin seems to reduce liver fat and prevent fibrosis progression in HIV-associated non-alcoholic fatty liver disease (NAFLD) [4].

However, tesamorelin has some side effects including injection-site reactions and common side effects associated with growth hormone therapy for instance headache, peripheral edema or arthralgia (joint stiffness) [2].

Frederika Malichová

Frederika Malichová

Frederika is a postgraduate researcher at the University of Cambridge, where she investigates new biomarkers for Frontotemporal Dementia and other tauopathies. Her research has been published at prestigious conferences such as the Alzheimer’s Association International Conference 2023. She obtained her BSc in Biomedical Sciences from UCL, where she worked closely with the UK Dementia Research Institute.